Precision BioSciences, Inc.
DYSTROPHIN GENE EXON DELETION USING ENGINEERED NUCLEASES
Last updated:
Abstract:
The invention relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the invention relates to a method of treating a patient with Duchenne Muscular Dystrophy comprising the removal of at least one exon from the dystrophin gene using engineered nucleases.
Status:
Application
Type:
Utility
Filling date:
25 Feb 2019
Issue date:
5 Sep 2019